News and Trends 8 Dec 2017 A London Biotech Aims to Overtake the Dry Eye Syndrome Market TopiVert has released the results of a clinical trial that the company believes yielded “the best proof of concept data in dry eye syndrome.” Based in London, the biotech company TopiVert is trying to enter the $3Bn market of dry eye syndrome with a drug with the potential to work better than the options currently […] December 8, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Dec 2017 French Biotech Misfires in Phase IIb Trial for Acute Myeloid Leukemia Erytech’s candidate, Graspa, has been unable to significantly improve overall survival in patients with acute myeloid leukemia during a Phase IIb trial. Erytech, based in Lyon, France, has developed an interesting approach to delivering drugs for the treatment of cancer and orphan diseases. The company’s eryaspase technology, Graspa, encapsulates L-asparaginase, in red blood cells. Graspa was used in combination with chemotherapy […] December 8, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 Scottish Biotech and Bluebird Bio to Develop Next Generation CAR-T Cells TC Biopharm has scored a deal with bluebird bio for the development of the next generation of CAR-T cells, a technology giving new hope to cancer patients. With the first two CAR-T therapies now in the market, the way we treat cancer is changing. This technology has shown to be effective in a high percentage of patients […] December 7, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 Taking Aim at Lung Cancer: New Triple Combination Therapy Boosts Survival A new first-line combination therapy for advanced non-squamous non-small-cell lung cancer improved progression-free survival during a Phase III trial. Scientists based at the Lung Clinic Grosshansdorf, Hamburg, and Centre Hospitalier Universitaire Vaudois, Lausanne, have presented the results of a Phase III study at the ESMO Immuno Oncology Congress 2017. The study was the first to investigate a combination […] December 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 7 Dec 2017 French Biotech’s Type 1 Diabetes Candidate Ready to Battle it Out with Big Pharma Adocia’s rapid-action insulin outperforms Novo Nordisk’s market approved treatment for type 1 diabetes during a Phase I study. Adocia specializes in new formulations of therapeutic proteins, particularly for the treatment of diabetes. Just last week, Adocia’s glucagon treatment for hypoglycemia was proved to be safe in a Phase I study. Today, the biotech has announced that its […] December 7, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2017 CRISPR Does it Again! Gene Editing Tool Identifies a New Leukemia Target Researchers from the Wellcome Trust Sanger Institute have reported that a new target for the treatment of leukemia has been found. A new drug target for acute myeloid leukemia (AML) has been identified that could open new avenues for the development of new treatments against the deadly disease. Researchers from the Wellcome Trust Sanger Institute have […] December 6, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 6 Dec 2017 Update: French Biotech Closes €27M IPO to be the First to Treat Rare Disease in Children Update (6/12/2017): Advicenne has raised a total of €27M on Euronext Paris, putting its market cap at €112M. Originally published on 21/11/2017 Advicenne is launching an IPO on Euronext Paris to raise the funds to bring the first treatment for dRTA, a rare disease of the kidneys, to the market. Advicenne, based in Nîmes, France, has officially […] December 6, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 5 Dec 2017 PayPal Co-Founder Backs Israeli Biotech Attacking NASH with an Antibody ChemomAb kicked off its antibody efforts as a company in 2011, and its $10M Series B has attracted none other than Peter Thiel. Israeli biotech has been attracting quite sizeable funds recently, largely those of UK investment outfit Arix Bioscience. Yesterday it was announced that Peter Theil, co-founder of PayPal and assassin of Gawker, led […] December 5, 2017 - 2 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2017 The Philippines Blocks Sanofi’s Dengue Vaccine for Safety Reasons Following alarming research about the safety of Sanofi’s dengue vaccine, Dengvaxia, The Philippines has halted its sale, distribution and marketing “to protect the general public.” Before Sanofi Pasteur distributed its dengue vaccine, Dengvaxia, there were some concerns that it would make people sicker. Last year, researchers from top American and British institutions confirmed these suspicions […] December 5, 2017 - 3 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 5 Dec 2017 Update: French Gene Therapy Yields Longer Term Sight Restoration, Eyes Phase III Update (05/12/2017): GenSight has reported a sustained effect of its treatment GS010, which has now been shown to restore sight in patients for at least 2.5 years after administration. Phase III results for the candidate are expected next year. Originally published 14/06/2017 GenSight has announced Phase I/II data revealing that its gene therapy technology can […] December 5, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
Best in Biotech 5 Dec 2017 Europe’s Brightest Stars: The 9 Best Biotech Companies of 2017 Tis the season for Glühwein, Tannenbäume, and lights in Berlin, and Labiotech is celebrating with its year-end lists of the top things that happened this year. First up, the best biotech companies of 2017! After the doozy of 2016 for biotech and pharma, things could only get better this year — and the European industry […] December 5, 2017 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 4 Dec 2017 Israeli Biotech Gets $30M Backing for its Immune Modulators for Severe Infections Atox Bio develops immune modulators to save patients with severe infections. An oversubscribed Series F financing will support its lead candidate through a Phase II trial. Atox Bio, which has operations in the US and Israel, develops immune modulators for patients with severe infections. The biotech was established at the Hebrew University of Jerusalem and Yissum. […] December 4, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email